Brief: Immunocore Presents Ovarian Cancer Expansion Data For ImmTAC Candidate IMC-C103C Targeting MAGE-A4

Immunocore Holdings

08/12/2022 13:18

Dec 8 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE PRESENTS OVARIAN CANCER EXPANSION DATA FOR
IMMTAC®
CANDIDATE IMC-C103C TARGETING MAGE-A4
    * IMMUNOCORE HOLDINGS PLC- IMC-C103C HAS MANAGEABLE SAFETY
PROFILE
AND DEMONSTRATED SIGNALS OF CLINICAL ACTIVITY
    * IMMUNOCORE HOLDINGS PLC - PHASE 1 TRIAL ENROLLED ALL
COMERS,
WITH VAST MAJORITY OF PATIENTS HAVING ZERO OR VERY LOW MAGE-A4
EXPRESSION
    * IMMUNOCORE HOLDINGS PLC - RECIST RESPONSE RATE WAS LOW IN
POPULATION WITH ZERO OR VERY LOW MAGE-A4 EXPRESSION

Source text for Eikon:  ID:nGNXc4QQS 
Further company coverage:  IMCR.O